Home›Lumacaftor And Ivacaftor›Lumacaftor And Ivacaftor + Midazolam

Does Lumacaftor And Ivacaftor Interact with Midazolam?

Lumacaftor And Ivacaftor and Midazolam have a unknown drug interaction according to U.S. FDA drug labeling data. Co-administration of ORKAMBI is not recommended with sensitive CYP3A substrates or CYP3A substrates with a narrow therapeutic index [see Warnings and Precautions (5.8) and Clinical Pharmacology (12.3) ] such as: Benzodiazepines : midazolam, triazolam (consider an alternative to these benzodiazepines). Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Unknown
Lumacaftor And Ivacaftor Class
Cystic Fibrosis Transmembrane Conductance Regulator Potentiator
Midazolam Class
Benzodiazepine
Management
Consult your pharmacist
Data Source
U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Lumacaftor And Ivacaftor and your doctor is considering prescribing Midazolam (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Never stop or change either medication without first consulting your healthcare provider
💊 Lumacaftor And Ivacaftor(Orkambi)+💊 Midazolam(Nayzilam)

Severity & Interaction Details

ℹ️
unknown
Interaction documented — severity unclassified
The FDA label notes an interaction but the severity is not classified in our dataset.
Severity scale
MinorContra
On record
Yes
Drug A class
Cystic Fibrosis Transmembrane Conductance Regulator Potentiator
Drug B class
Benzodiazepine
Source
FDA drug label - lumacaftor and ivacaftor

What this means in plain English

Co-administration of ORKAMBI is not recommended with sensitive CYP3A substrates or CYP3A substrates with a narrow therapeutic index [see Warnings and Precautions (5.8) and Clinical Pharmacology (12.3) ] such as: Benzodiazepines : midazolam, triazolam (consider an alternative to these benzodiazepines).

About Lumacaftor And Ivacaftor and Midazolam

Lumacaftor And Ivacaftor is a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator, while Midazolam is a Benzodiazepine. You may recognize them by the brand names Orkambi and Nayzilam. Lumacaftor And Ivacaftor is taken by mouth, whereas Midazolam is given by intravenous (IV) infusion. Midazolam additionally carries an FDA boxed warning, the FDA's strongest safety alert.

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Lumacaftor And Ivacaftor and Midazolam against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
Data integrity: Every interaction shown is extracted directly from official U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NIH) — no interactions are invented, inferred, or manually edited. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.